Skip to main content
Clinical Trials/NCT06598501
NCT06598501
Not yet recruiting
Not Applicable

Repetitive Transcranial Magnetic Stimulation (rTMS) and Cognitive Behavioral Therapy (CBT) in the Management of Gambling Disorder in Indonesia: a Pilot and Feasibility Study

Indonesia University0 sites10 target enrollmentOctober 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Gambling Disorder
Sponsor
Indonesia University
Enrollment
10
Primary Endpoint
Improvement in pathological gambling score
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

Treatment options for gambling disorder (GD) remain limited, with no pharmacotherapy proven effective. As of date, cognitive behavioral therapy (CBT) is the preferred therapy for GD, but the improvements often require months to show, highlighting the need for a more comprehensive therapy. Repetitive transcranial magnetic stimulation (rTMS) is a promising treatment modality in alleviating craving. Studies have shown potential benefit of combining both CBT and rTMS in substance addiction, but not in GD. Thus, this study aims to determine the feasibility and efficacy of rTMS and CBT combination therapy in the management of GD in Indonesia.

Registry
clinicaltrials.gov
Start Date
October 2024
End Date
April 2025
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Kristiana Siste

Dr. dr. Kristiana Siste, SpKJ(K) - Head of Department of Psychiatry, Faculty of Medicine, Indonesia University

Indonesia University

Eligibility Criteria

Inclusion Criteria

  • Subjects with pathological gambling (SOGS score ≥ 5)
  • Subjects aged 18-70 years old
  • Subjects who understand Bahasa Indonesia
  • Subjects who agree to participate and receive treatment

Exclusion Criteria

  • Subjects with history of psychotic disorder and personality disorder according to ICD-11
  • Subjects with severe neurological disorder comorbidities, which cause seizure or loss of consciousness
  • Subjects with intellectual disability
  • Subjects with history of neurostimulation
  • Subjects with history of medical implant
  • Subjects currently or expecting pregnancy
  • Subjects fulfilling diagnostic criteria of substance use disorder in the last 6 months

Outcomes

Primary Outcomes

Improvement in pathological gambling score

Time Frame: Baseline (week 0), interim assessment (week 3), post-intervention (week 6), follow up at 3 months and 6 months after intervention

South Oaks Gambling Screen (SOGS), Indonesian version, with minimum score of 0 and maximum score of 20. A score of 0-2 indicates no pathological gambling; a score of 3-4 indicates problems with gambling, and a score of 5 or more indicates that the subject is a probable pathological gambler. Lower score indicates a better outcome.

Improvement in gambling symptoms severity

Time Frame: Baseline (week 0), interim assessment (week 3), post-intervention (week 6), follow up at 3 months and 6 months after intervention

Gambling Symptoms Assessment Scale (G-SAS), Indonesian version, with minimum score of 0 and maximum score of 48. Interpretations: Mild (8-20), Moderate (21-30), Severe (31-40), and Extreme (41-48). Lower score indicates a better outcome.

Improvement in gambling urge

Time Frame: Baseline (week 0), interim assessment (week 3), post-intervention (week 6), follow up at 3 months and 6 months after intervention

Gambling Urge Scale (GUS), Indonesian version, with minimum score of 0 and maximum score of 42. Lower score indicates a better outcome.

Improvement in gambling related cognitive distortions

Time Frame: Baseline (week 0), interim assessment (week 3), post-intervention (week 6), follow up at 3 months and 6 months after intervention

Gambling Related Cognitions Scale (GRCS), Indonesian version, with 5 cognitive distortion domains. Lower score indicates a better outcome.

Secondary Outcomes

  • Improvement in gambling-related cognitive functions(Baseline (week 0), interim assessment (week 3), post-intervention (week 6), follow up at 3 months and 6 months after intervention)
  • Improvement in depression symptoms(Baseline (week 0), post-intervention (week 6), follow up at 3 months and 6 months after intervention)
  • Improvement in self-reported psychological distress(Baseline (week 0), post-intervention (week 6), follow up at 3 months and 6 months after intervention)
  • Improvement of overall severity of illness(Baseline (week 0), interim assessment (week 3), post-intervention (week 6), follow up at 3 months and 6 months after intervention)

Similar Trials